Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)
NCT06439277 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 3, 2024
- Completion date
- December 31, 2030
- Enrollment
- 300 (estimated)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.